...a CD37-targeted radionuclide therapy to treat lymphoma (see “Radiotherapy Blasts Forward” ). Bone healing company Bioventus Inc....
...Pharmaceuticals Inc. Freeline Therapeutics Ltd. Seres Therapeutics Inc. Urovant Sciences Ltd. UroGen Pharma Ltd. Iveric bio Inc. Nordic Nanovector ASA Viracta Therapeutics Inc. Bioventus Inc....

...chimera plus the granule-COL1 matrix increased bone remodeling compared with pretreatment baselines. Next steps by Bioventus Inc....
...repair. TARGET/MARKER/PATHWAY: Bone morphogenetic protein 2 (BMP2); BMP6; activin A LICENSING STATUS: Patented; licensed to Bioventus Inc....
...published online Apr. 24, 2019 doi:10.1126/scitranslmed.aar4953 CONTACT: Howard J. Seeherman, Bioventus Inc., Durham, N.C. email: hseeherman@gmail.com Claire Quang Bioventus Inc. Activin...

...He was CFO and head of business development at AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX). Orthobiologics company Bioventus Inc....

...15. He will succeed Edward Borkowski, who is leaving the company. Price was CFO of Bioventus Inc....

...Galderma granted Bioventus U.S. rights to commercialize Durolane for pain associated with knee osteoarthritis. Bioventus said...
...to disclose financial terms. Galderma S.A. , Lausanne, Switzerland Bioventus Inc. , Durham, N.C. Business: Neurology Shannon Lehnbeuter Durolane Bioventus Inc. Galderma...

...WAC) is $345 per 2 mL injection; one treatment comprises three injections of hyaluronic acid. Bioventus Inc....

...Neurology Date announced: 2016-08-02 Type: IPO Underwriters: JPMorgan; Piper Jaffray; Stifel, Nicolaus; Leerink Partners Note: Bioventus...

...million Price: $16-$18 Underwriters: JPMorgan; Piper Jaffray; Stifel, Nicolaus; Leerink Partners Overallotment: 1.3 million Note: Bioventus...

...$150 million Shares: TBD Price: TBD Underwriters: JPMorgan; Piper Jaffray; Stifel, Nicolaus; Leerink Partners Note: Bioventus...

...To be raised (A) Status (B) AdAlta Ltd. (ASX) 7/8/16 Up to A$10M ($7.4M) Preclin Bioventus Inc....